Description

Parabolan

Tren in general is a 19-nor anabolic steroid in the same family as nandrolone. There are mainly 3 types of tren usually seen in PED circles: Tren acetate, Tren enanthate, and Tren Trenbolone hexahydrobenzylcarbonate aka Parabolan aka Hexabolan. Tren acetate was/is used for cattle to make them bigger and is a vet drug; it was briefly approved for use by humans under the name Finaject but that was short lived between 1980-1987. Parabolan was pharmaceutically manufactured for human use in France several decades ago (discontinued in 1997) and approved for human use for the treatment of muscle wasting.

The main difference between the drugs is the ester at the end (look at to the right of the chemical structures and you will the difference between the esters). Essentially, what this translates to is that the acetate ester is faster acting than the hexahydrobenzylcarbonate ester which is slower acting (about 3 days vs 14 days). However, other than that the drugs are virtually the same. To say that parabolan is safer than tren (acetate) is not accurate whatsoever.

Tren offers some great PED benefits, but the drug can be quite harsh on the system. Like any other drug, how harsh is mainly dose dependent and on length of exposure.

Parabolan was clinically prescribed to be used at dose of less than 100 mg per week. Unfortunately, many bodybuilders take 3-6 times this dosage for prolonged periods of time and they “stack” it with other PEDs on top of that. Hence, here is where the problem lies. Excessive dosages over years on end leads to major problems, especially when you are not monitoring your health such as blood pressure, fasting blood glucose levels and other blood work such as LDL, HDL, triglycerides, hematocrit, liver enzymes, etc and check in with your doc.

We describe a case of a 21-year-old male bodybuilder who overdosed on Parabolan (trenbolone acetate) because of its anabolic activity. The patient, with no previous medical history, experienced pruritus and yellow discoloration of the skin and sclerae. Basic biochemical laboratory examination revealed signs of cholestasis with a serum bilirubin level of up to 65.5 mg/dl. Because supportive medical treatment was ineffective, the patient was treated with the molecular adsorbent recirculating system (MARS). Five MARS cycles lasting from 8 to 12 hours were performed every second day. The procedure was well tolerated by the patient and resulted in a sustained relief of pruritus. At the 2-month follow-up visit the plasma bilirubin level had decreased to 2 mg/dl.